Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio